Mammoth Biosciences disclosed preclinical nonhuman primate data and announced plans for a first clinical trial of its lead gene‑editing program aimed at permanently lowering triglycerides. Co‑founded by Jennifer Doudna, Mammoth’s program uses in‑vivo editing technologies; the company presented monkey data supporting target engagement and tolerability. The move toward human testing marks a step for CRISPR‑based metabolic interventions and will be watched for delivery, durability, and safety signals as the field expands beyond rare monogenic targets.